New Vaxcyte Vaccine Has Protected Against 31 Bacterial Strains
Adults age 50 and older may soon have a more comprehensive option for preventing pneumococcal disease.
Updated on Oct. 5, 2026 in COVID-19
Live Poll
Do you believe newer medical vaccines are generally more effective than the options currently available?
Vaxcyte reported that its experimental vaccine, VAX-31, successfully met its primary endpoints in a Phase 3 clinical trial. The findings position the new vaccine as a potential alternative to existing options for adults age 50 and older.
Why it matters
The development marks a shift in the vaccine landscape, as researchers aim to cover a broader array of bacteria responsible for serious illness. If approved, this vaccine could offer more extensive protection against pneumococcal disease than current standard-of-care options.
In a Phase 3 trial of 3,500 adults age 50 and older, VAX-31 met its primary endpoints for immunogenicity. The study directly randomized participants to receive either VAX-31, Prevnar, or Capvaxive to measure antibody responses against various bacterial strains.
The players
Vaxcyte
A California-based biotechnology company focused on developing next-generation vaccines for infectious diseases.
Pfizer
A pharmaceutical manufacturer known for its portfolio of vaccines, including the Prevnar pneumococcal series.
Merck
A global healthcare firm that develops vaccines and therapeutics, including the Capvaxive pneumococcal vaccine.
The details
The vaccine works by stimulating the immune system to produce antibodies that target specific bacterial surface proteins, known as serotypes. By covering 31 unique strains, VAX-31 aims to provide a wider shield against the bacteria that cause invasive pneumococcal disease. Researchers assessed the effectiveness of this approach by quantifying antibody strength generated by the trial participants following vaccination.
Timeline
October 5, 2026: Vaxcyte announced the trial results.
Health Landscape
This development reflects the ongoing evolution of the pneumococcal vaccine market, where manufacturers are actively increasing the number of bacterial serotypes covered by their products. The trial results mark a significant step in the competition to define the next standard of care.
As new vaccine options emerge, it is worth discussing your individual immunization needs and the timing of your next pneumococcal dose with your physician. They can help you evaluate which current options align best with your health history and risk factors for respiratory infection.
The takeaway
The move toward vaccines with higher serotype coverage could provide more robust protection against common bacterial threats. Discuss your current vaccination status with your doctor to determine if you are up to date on recommended preventative care for your age group.
Further reading
For context on how new immunization technologies are tested and implemented, visit COVID-19.
Live Poll
Do you believe newer medical vaccines are generally more effective than the options currently available?
